Document Detail


Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL).
MedLine Citation:
PMID:  17297594     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients with systemic lupus erythematosus (SLE) are at increased risk of developing non-Hodgkin's lymphoma (NHL), but features of SLE associated with NHL are not well described. The objective of this study was to describe SLE characteristics, laboratory serologies, and medication histories in patients who subsequently develop NHL. Two thousand twenty patients with SLE were identified using the online Partners' patient database research tool between October 1992 and June 2005. We confirmed the diagnoses of SLE and NHL and sought details of medical history and treatment by medical record review. Eleven patients with NHL without coexisting rheumatoid arthritis, Sjögren's, or HIV were identified; seven of these (64%) had a diffuse large B cell lymphoma subtype, and 83% of those stained were Epstein-Barr virus (EBV) negative. The mean duration of SLE at NHL diagnosis was 17.8 years (range 1.6-41.8), and the mean Systemic Lupus International Collaborative Clinics/American College of Rheumatology damage index was 1.9. Seven patients (64%) had SLE hematologic involvement, four had anti-dsDNA antibodies, and four had anti-phospholipid antibodies. One patient had significant renal disease. All patients had arthritis and had received antimalarial therapy. Five of 11 patients had received other treatments for SLE, including cyclophosphamide, imuran, methotrexate, and/or sulfasalazine. Diffuse large B cell lymphoma was the most common subtype of NHL, and most were EBV negative. Although disease duration was fairly long and end organ damage moderately severe in this group of patients, renal disease and the use of immunosuppressive chemotherapeutic agents were rare and did not appear to confer an increased risk of NHL development.
Authors:
Jennifer K King; Karen H Costenbader
Related Documents :
1006524 - The clinical significance of raynaud's syndrome.
8025584 - Avascular osteonecrosis in patients with sle: relation to corticosteroid therapy and an...
15710594 - Advanced waldenström's macroglobulinemia: usefulness of morel's scoring system in esta...
9672994 - Clinical diagnosis found in patients with raynaud's phenomenon: a multicentre study.
14636754 - Examination of soluble fas (sfas) and soluble fas ligand (sfasl) in patients with burns.
14872464 - Concerns of patients actively contemplating total knee replacement: differences by race...
Publication Detail:
Type:  Journal Article; Multicenter Study     Date:  2007-02-13
Journal Detail:
Title:  Clinical rheumatology     Volume:  26     ISSN:  0770-3198     ISO Abbreviation:  Clin. Rheumatol.     Publication Date:  2007 Sep 
Date Detail:
Created Date:  2007-07-30     Completed Date:  2007-10-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8211469     Medline TA:  Clin Rheumatol     Country:  Belgium    
Other Details:
Languages:  eng     Pagination:  1491-4     Citation Subset:  IM    
Affiliation:
Division of Rheumatology, University of California Los Angeles, 1000 Veteran Avenue, Rehab Center Room 32-59, Los Angeles, CA 90095, USA. jkking@mednet.ucla.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Female
Humans
Immunosuppressive Agents / adverse effects
Kidney Diseases / complications,  etiology
Lupus Erythematosus, Systemic / complications*
Lymphoma, Non-Hodgkin / complications*,  epidemiology
Male
Middle Aged
Retrospective Studies
Risk Factors
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Erythropoietin attenuates the development of experimental autoimmune myocarditis.
Next Document:  Raman spectroscopy and multivariate analysis of serum samples from breast cancer patients.